Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Gentle nasal spray vaccines against COVID, the flu and RSV are coming. They may work better than shots in the arm ...

The updated mRNA vaccines from Moderna and Pfizer-BioNTech target the KP ... Why we see such relatively rapid waning immunity with SARS-CoV-2 isn’t clear. “I’ve seen reports of multiple infections ...

Liberty Media Corporation ("Liberty Media" or "Liberty") (NASDAQ: FWONA, FWONK, LLYVA, LLYVK) today reported third quarter 2024 results. Headlines include(1): Completed ...

He is home by the fire with his beloved wife, Christine, and close friends when the call comes, informing him that the phase 3 clinical trial data have projected the Pfizer–BioNTech COVID ... never to ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

No FDA-approved rapid tests exist that specifically test for H5N1, and the first near-point-of-care test for mpox was ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial ...